Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.07 | -0.05 | 19.71 |
| FCF Yield | -52.03% | -29.73% | -33.62% | -20.46% |
| EV / EBITDA | -2.95 | -1.42 | -2.22 | -4.73 |
| Quality | ||||
| ROIC | -88.69% | -44.52% | -138.93% | -81.08% |
| Gross Margin | 85.57% | 75.51% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.68 | 0.74 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -91.72% | 5.66% | 0.92% | -110.59% |
| Safety | ||||
| Net Debt / EBITDA | -0.99 | 1.52 | 0.34 | 0.68 |
| Interest Coverage | -3.85 | -3.99 | -6.32 | -19.90 |
| Efficiency | ||||
| Inventory Turnover | 2.49 | 0.14 | 0.00 | 0.00 |
| Cash Conversion Cycle | -77.85 | -24,024.76 | -5,885.33 | -3,607.97 |